Amphastar Pharmaceuticals (AMPH) Total Non-Current Liabilities (2014 - 2026)
Amphastar Pharmaceuticals (AMPH) posted quarterly Total Non-Current Liabilities of $868.8 million for Q1 2026, up 2.15% year-over-year from $850.6 million in Q1 2025, and up 4.11% quarter-over-quarter from $834.6 million in Q4 2025.
Amphastar Pharmaceuticals (AMPH) Total Non-Current Liabilities (2014 - 2026) Analysis & Trends
Amphastar Pharmaceuticals' Total Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $868.8 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 2.15% year-over-year to $868.8 million; the TTM figure through Mar 2026 stood at $868.8 million (up 2.15% YoY), while the FY2025 annual figure was $834.6 million, up 1.25% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $868.8 million, up from $834.6 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $942.3 million in Q3 2023, with the low at $206.1 million in Q4 2022.
- The 5-year median for Total Non-Current Liabilities is $824.2 million (2024), against an average of $658.2 million.
- The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities jumped 354.46% in 2023, then fell 16.11% in 2024.
- Amphastar Pharmaceuticals' Total Non-Current Liabilities stood at $206.1 million in 2022, then soared by 320.87% to $867.4 million in 2023, then decreased by 4.98% to $824.2 million in 2024, then rose by 1.25% to $834.6 million in 2025, then gained by 4.11% to $868.8 million in 2026.
- Business Quant data shows AMPH's Total Non-Current Liabilities at $868.8 million in Q1 2026, $834.6 million in Q4 2025, and $882.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 334.00 Mn |
| 10 | Amphastar Pharmaceuticals | 943.15 Mn | 653.02 Mn | 93.47 Mn | 946.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 946.17 Mn |
| Mar 31, 2026 | 868.85 Mn |
| Dec 31, 2025 | 834.57 Mn |
| Sep 30, 2025 | 882.52 Mn |
| Jun 30, 2025 | 850.89 Mn |
| Mar 31, 2025 | 850.57 Mn |
| Dec 31, 2024 | 824.23 Mn |
| Sep 30, 2024 | 790.46 Mn |
| Jun 30, 2024 | 759.37 Mn |
| Mar 31, 2024 | 883.98 Mn |
| Dec 31, 2023 | 867.43 Mn |
| Sep 30, 2023 | 942.27 Mn |
| Jun 30, 2023 | 771.40 Mn |
| Mar 31, 2023 | 209.90 Mn |
| Dec 31, 2022 | 206.10 Mn |
| Sep 30, 2022 | 207.34 Mn |
| Jun 30, 2022 | 217.88 Mn |
| Mar 31, 2022 | 221.22 Mn |
| Dec 31, 2021 | 210.35 Mn |
| Sep 30, 2021 | 206.62 Mn |